Fetroja antimicrobial spectrum of activity1

Fetroja is active both in vitro and in clinical infections against: Enterobacteriaceae (E coli, E cloacae complex, K pneumoniae, and P mirabilis) and P aeruginosa


Fetroja is active in vitro against the following but the clinical significance is unknown. At least 90% of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefiderocol: A baumannii, S maltophilia, Serratia marcescens, Citrobacter freundii complex, Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus vulgaris, and Providencia rettgeri

Fetroja is active against pathogens with problematic resistance mechanisms1-4

Pathogena Resistance mechanisms Fetroja activity in vitro
Enterobacteriaceae ESBLs: TEM, SHV, CTX-M, OXA
AmpC, AmpC-type ESBL (CMY)
Serine-carbapenemases such as KPC, OXA-48
Metallo-carbapenemases such as NDM and VIM
K pneumoniae OmpK35/36 porin deletion
E coli mcr-1 (colistin resistance)
P aeruginosa AmpC
Serine-carbapenemase GES
Metallo-carbapenemase VIM
OprD porin deletion
A baumannii OXA-23, OXA-24/40, OXA-51, OXA-58
S maltophilia Intrinsic carbapenem resistance
Swipe table for more
  • Fetroja does not cause induction of AmpC β-lactamase in P aeruginosa or E cloacae
a Activity demonstrated against certain isolates.
In vitro activity does not necessarily correlate with clinical efficacy.

No cross-resistance with other antibacterials has been identified with Fetroja